ENLIVEN THERAPEUTICS, INC.

Highlights Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2024 am IST			5-day change	1st Jan Change
22.75 ^USD	+3.46%		+11.30%	+64.38%

11/06	Baird Initiates Enliven Therapeutics With Outperform Rating, $32 Price Target	MT
29/05	Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Enliven Therapeutics Q1 Loss Narrows	15/05	MT
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04	CI
North American Morning Briefing : Investors -2-	21/03	DJ
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03	CI
Enliven Therapeutics Q3 Loss Narrows	10/11	MT
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders for approximately $340 million in a reverse merger transaction.	23/23/23	CI
Enliven Therapeutics, Inc. entered into a definitive merger agreement to acquire IMARA Inc. from a group of shareholders in a reverse merger transaction.	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer